Evotec SE

Dear ladies and gentlemen, welcome to the conference call of Evotec SE. At our customer's request, this conference will be recorded. As a reminder, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. If any participant has difficulty hearing the conference, please press star key followed by zero on your telephone for operator assistance. May I now hand you over to Dr. Werner Landtaler, CEO, Who will lead you through this conference? Please go ahead, sir.

Good afternoon. This is Werner speaking from sunny Hamburg. Welcome to our HAFU report 2020. You can find the supporting slides for this call on the web as usual. We often get asked, what's the purpose of Evotech? and it's very simple. We design and apply innovative technologies and processes across all modalities in order to expand access to more precise medicines together with our partners. Or if you want it even more simple, we are the drug discovery and drug development autobahn. Especially in times of a pandemic crisis, Acceleration and even more speed on this Autobahn is needed today more than ever before. I'm here together with my team, our CFO Enno, our CO Craig, our CSO Cord, and it's great to also have Volker Braun for the first time here together with us in the room, who will be our key contact for investors and analysts in the future.

If you go to page number three of the presentation,